Goldman Sachs analyst Madhu Kumar maintained a Hold rating on Passage Bio (PASG – Research Report) today. The company’s shares closed today at $1.00.
According to TipRanks, Kumar is a 5-star analyst with an average return of 17.3% and a 49.85% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Apellis Pharmaceuticals, and Arrowhead Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Passage Bio with a $5.00 average price target.
See the top stocks recommended by analysts >>
PASG market cap is currently $55.16M and has a P/E ratio of -0.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Read More on PASG:
- Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
